At Third Thursday @ Three, hosted by Kiln Lehi, Utah founders pitched startups tackling women's health, venture inefficiencies, and service industry gaps — showcasing a bold, hands-on spirit driving the state’s next wave of innovation.

Purgo Scientific (South Jordan, UT) appoints medical device innovator Tim Nieman to its Board of Directors as it accelerates the path to commercialization of the Purgo Pouch, a breakthrough localized antibiotic delivery system for surgical infections in humans and animals

SchoolAI (Lehi, UT) today unveiled a major platform update, introducing AI-powered tools to personalize learning, support educators, and scale student success. The release positions SchoolAI as a national leader in responsible, classroom-centered AI implementation.

SkillCo (Orem, UT) is expanding its skills-to-career platform after securing renewed support from UVU and raising $300K. It aims to turn the traditional degree into a skill based portfolio that connects education directly to careers, and helping Utah remain a leader in outcome-driven higher ed.

Torus (South Salt Lake, UT) leads Ultion Technologies' (Las Vegas, NV) Series A to scale U.S.-made LFP battery production, strengthening domestic energy storage resilience and reducing dependence on foreign supply chains.

Nusano (West Valley City, UT) has achieved a key accelerator milestone, enabling the simultaneous production of 12 radioisotopes through its advanced ion beam platform, marking a breakthrough in scalable, high-yield radioisotope manufacturing.

Jessica Curran, VP of Data Science at Health Catalyst (South Jordan, UT), shares how her work in healthcare data science improves patient care, empowers clinicians, and opens doors for women and remote professionals in tech.

Neuronova (Provo, UT) has developed a vibroacoustic therapy chair designed to boost dopamine production and relieve anxiety, pain, and more—an early-stage innovation blending neuroscience, engineering, and anecdotal breakthroughs. The company will soon begin a $3 million NIH-funded Phase II study.